TD-9855 is an investigational norepinephrine and serotonin reuptake inhibitor (NSRI). The compound successfully completed a Phase 2 study in patients with fibromylagia, demonstrating statistically significant and clinically meaningful improvements in pain and core symptoms at the highest dose tested compared to placebo. We are assessing the potential use of TD-9855 in cardiovascular conditions such as neurogenic orthostatic hypotension (nOH).
TD-0714 is an internally-discovered selective inhibitor of neprilysin (NEP), the enzyme responsible for degradation of natriuretic peptides ANP, BNP and CNP. By inhibiting NEP, TD-0714 elevates the levels of these peptides, which may exert protective cardiac and renal effects including vasodilation, diuresis, natriuresis, reversal of maladaptive changes in heart, blood vessels and kidney, prevention of fibrosis, and prevention of end-organ damage. We have specifically designed TD-0714 to possess certain key features, including low renal clearance, the potential to be administered once daily, and the flexibility to be combined with other approved and investigational drugs.
TD-0714 is the lead drug candidate in our NEP inhibitor program. This program is designed to develop best-in-class selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. We are conducting a Phase 1 clinical study of TD-0714.